Table 5.

Exploratory analyses of AVC progression among those with AVC > 0 at baseline: Linear regression models of absolute AVC progression incorporating baseline Agatston score (AGS) as a predictor, stratified above and below median baseline AVC, and of relative AVC progression.

	Absolute Progression						Relative Progression*
Characteristic	Full Cohort (n=738)		Below Median (AGS <59, n=366)		Above Median (AGS >59, n=372)		Full Cohort (n=738)
	β‡ (95% CI)	p-value	β‡ (95% CI)	p-value	β‡ (95% CI)	p-value	β‡ (95% CI)	p-value
Baseline AGS	0.20 (0.05, 0.35)	0.009			0.21 (0.05, 37.2)	0.01	Not Included
Age
Gender							0.1 (−0.01, 0.22)	0.07
Blood Pressure
Systolic BP
Diastolic BP	−12.6 (−27.2, 2.0)	0.09			−23.0 (−49.6, 3.6)	0.09
Creatinine
≤0.9 mg/dL			3.7 (−5.2, 12.6)	0.41
1.0 mg/dL			reference
≥1.1 mg/dL			11.3 (1.2, 21.3)	0.03

^†Variables chosen from backwards selection and also included adjustments for follow up time and scanner types. Variables without risk estimates were not independently associated with AVC progression and were not retained in the final model. Other variables included in the analysis included male gender, family history of MI, the use of antihypertensive medications, diabetes category (none, impaired fasting glucose, diabetes), smoking status (never, former, current), pack years, cholesterol (LDL, HDL and triglycerides), CRP (log), fibrinogen and creatinine category (≤0.9, 1.0, ≥1.1).

^*Relative progression defined as difference in log(AGS+25).

^‡β = difference in average progression per one unit change in predictor or in comparison to reference group.

Abbreviations: AGS = Agatston score, BP = blood pressure.